HOME >> BIOLOGY >> NEWS
Cost-effectiveness of treating multidrug-resistant tuberculosis

Researchers have made predictions as to how the tuberculosis (TB) epidemic in Peru might progress over the next 30 years, depending on what measures are used to fight it. They considered the five different approaches to treating drug-resistant TB that are open to the Peruvian health authorities.

TB is a growing problem worldwide. Most cases can be treated effectively with a standard treatment (known as 'DOTS', which stands for 'Directly Observed Therapy Short-Course') but an increasing number of cases are resistant to all the various 'first-line' treatment drugs; this is known as multi-drug resistant (MDR) TB. MDR-TB must be treated with 'second-line' drugs. There are several different options; for example, doctors could give second-line drugs whenever a first attempt at treatment has failed, or only use these drugs in cases where tests have confirmed MDR-TB to be the problem. MDR-TB cases could all be given the same standard treatment or, based on tests, each could have 'individualized' treatment.

The researchers used a method called 'modelling'. They performed calculations based on information already available about TB in Peru, where there are 120 new TB infections per 100,000 people every year and 4.5% of existing cases have MDR-TB. They concluded that use of second-line drugs would be cost-effective for Peru and that, despite the extra costs of individualized treatment, this is the best option. The results will be of interest in other developing countries. The researchers say, "In other settings, the attractiveness of strategies using second-line drugs will depend on TB incidence, MDR burden, and the available budget, but simulation results suggest that individualized regimens would be cost-effective in a wide range of situations". They also stress it is important for the standard first-line DOTS treatment to be made widely available.


'"/>

Contact: Andrew Hyde
ahyde@plos.org
44-122-346-3330
Public Library of Science
3-Jul-2006


Page: 1

Related biology news :

1. Cost-effectiveness study of three antimalarial drug combinations in Tanzania
2. Brain blood flow gives clues to treating depression
3. New strategy for treating allergic disorders
4. Developer of new method for treating bone defects wins WPI Entrepreneurship Award
5. UCF nanoparticle offers promise for treating glaucoma
6. Cisplatin is more effective than carboplatin for treating nonsmall cell lung cancer
7. 8 plants from South Africa may hold potential for treating high blood pressure
8. Arctic ice retreating more quickly than computer models project
9. Nanotechnology offers hope for treating spinal cord injuries, diabetes and Parkinsons disease
10. Discovery in plants suggests entirely new approach to treating human cancers
11. Preventing and treating lung cancer -- ESMO explores collaboration to fight cancer on all fronts

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
Cached News: